X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The proceeds of the financing will be used to drive further development of Senda’s proprietary programmable medicines platform and advance its first programs into clinical testing. Senda is developing a new class of SendRNA™ medicines.
Lead Product(s): SendRNA Therapeutic
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Flagship Pioneering
Deal Size: $123.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing August 16, 2022
Details:
Senda Biosciences has entered into a strategic collaboration with Nestlé Health Science for the development of novel nutritional therapies for a wide range of metabolic conditions, including obesity and glycemia.
Lead Product(s): Nutritional therapies
Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Nestle Health Sciences SA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 26, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
